Adam Craig, M.D., Ph.D.

Adam Craig, M.D., Ph.D., is a biotechnology executive with over 25 years of global experience in drug development and commercialization, particularly in oncology, hematology, and rare diseases. He served as President and CEO of CTI BioPharma leading to the approval and commercialization of Vonjo®. He is currently Executive Chairman of X4 Pharmaceuticals and was recently interim CEO of Stratus Therapeutics (formerly Garuda Therapeutics). Dr Craig previously held CMO and senior development roles at Sunesis Pharmaceuticals and Chemgenex Pharmaceuticals and currently serves on the board of Stratus Therapeutics. Dr. Craig is a Member of the Royal College of Physicians (U.K.) and holds medical and doctoral degrees from the University of London, a Ph.D. in Molecular Oncology from Leeds University, and an MBA from the Open Business School.